NeuroPace Inc

Rule 10b5-1 Trading Plans

During the three months ended June 30, 2026, Lisa Andrade, adirector of the Company, adopted a written trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan was adopted on June 3, 2026 and provides for the exercise of up to 27,380 stock options and the sale of a number of shares sufficient to cover the associated exercise costs, estimated tax withholding obligations, and customary brokerage fees (“sell to cover”). The earliest sell date under the plan is September 2, 2026. The plan will terminate on the earlier of June 3, 2027, or the occurrence of certain other events specified in the plan, including full execution of all trades thereunder or termination by either party upon written notice.

No other director or officer (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated any contracts, instructions, or written plans for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K during the three months ended June 30, 2026.